Ardelyx (ARDX) Announces 9:4 FDA Vote AdCom Vote Favoring XPHOZAH
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- S&P 500, Nasdaq futures slip after tech rally; Warsh's speech awaited
- Oil holds steady, on track for weekly fall on US-Iran talks stalemate
- Dollar heads for weekly gain as Warsh remarks awaited
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Ovintiv adds 41,000 acres in Permian and Montney deals
- Russia says it could strike UK military targets in response to Kyiv's use of British missiles
Ardelyx (ARDX) Director Mott Buys $1M in Stock Following Positive FDA Panel
November 17, 2022 4:14 PM ESTArdelyx (NASDAQ: ARDX) Director, David Mott, bought 567,000 shares on 11/17/22 at $1.7648.
The value of the purchase was just over $1 million and follows a positive FDA panel vote.
... MoreArdelyx, Inc (ARDX) Stock 'Acting Poorly' Despite 50% Up Move - Citi
November 17, 2022 1:01 PM ESTCiti analyst Yigal Nochomovitz reiterated a Buy rating and $10.00 price target on Ardelyx, Inc (NASDAQ: ARDX), saying with the stock up less than 50% it is acting poorly (only up... More
